Oklahoma Life Science Fund

Managing Partners William Paiva and Sean Finlayson lead the firm. Paiva is the Tulsa-based contact; Finlayson is reachable via a Kansas area code. No additional investment committee members or partners are disclosed on the firm's materials.

The firm's geographic anchor in Oklahoma provides a structural sourcing advantage — it screens life science opportunities that are physically or academically tied to the state, a region where institutional venture capital rarely operates at seed stage. Inoveon's founder publicly credited OLSF with attracting a broad base of external funding through its expertise and focus.

The portfolio spans therapeutics (Crohn's disease, ulcerative colitis, sickle cell disease), medical devices (smartphone ECG, laser-based sensors), diagnostics and molecular cancer therapies, and digital health (cognitive testing apps, mobile benefit management). The firm also backs healthcare services such as managed on-site clinics and therapy staffing.

Three funds are listed — OLSF I, OLSF II, and OLSF III — all with active portfolio company rosters on the firm's website. The firm has not disclosed fund sizes, vintage years, or current deployment status for any of the three vehicles.

Yes. The firm's model relies on syndication: Inoveon's founder cited OLSF's role in helping attract external institutional funding, and the breadth of portfolio companies — many requiring scaled clinical trials — implies co-investor participation beyond a single small fund's capacity.